SK148999A3 - Gastroretentive controlled release microspheres for improved drug delivery - Google Patents

Gastroretentive controlled release microspheres for improved drug delivery Download PDF

Info

Publication number
SK148999A3
SK148999A3 SK1489-99A SK148999A SK148999A3 SK 148999 A3 SK148999 A3 SK 148999A3 SK 148999 A SK148999 A SK 148999A SK 148999 A3 SK148999 A3 SK 148999A3
Authority
SK
Slovakia
Prior art keywords
composition according
composition
water
active ingredient
drug
Prior art date
Application number
SK1489-99A
Other languages
English (en)
Slovak (sk)
Inventor
Lisbeth Illum
He Ping
Original Assignee
West Pharm Serv Drug Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West Pharm Serv Drug Res Ltd filed Critical West Pharm Serv Drug Res Ltd
Publication of SK148999A3 publication Critical patent/SK148999A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK1489-99A 1997-05-24 1998-05-22 Gastroretentive controlled release microspheres for improved drug delivery SK148999A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9710699.1A GB9710699D0 (en) 1997-05-24 1997-05-24 Gastro-retentive controlled release system
PCT/GB1998/001513 WO1998052547A1 (en) 1997-05-24 1998-05-22 Gastroretentive controlled release microspheres for improved drug delivery

Publications (1)

Publication Number Publication Date
SK148999A3 true SK148999A3 (en) 2000-07-11

Family

ID=10812970

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1489-99A SK148999A3 (en) 1997-05-24 1998-05-22 Gastroretentive controlled release microspheres for improved drug delivery

Country Status (22)

Country Link
US (1) US6207197B1 (es)
EP (1) EP0984774B1 (es)
JP (1) JP2001525848A (es)
KR (1) KR20010012857A (es)
CN (1) CN1257425A (es)
AR (1) AR012854A1 (es)
AT (1) ATE270880T1 (es)
AU (1) AU737818B2 (es)
BR (1) BR9809453A (es)
CA (1) CA2285580A1 (es)
DE (1) DE69825049T2 (es)
ES (1) ES2226137T3 (es)
GB (2) GB9710699D0 (es)
HU (1) HUP0002935A3 (es)
IL (1) IL132453A0 (es)
NO (1) NO995753L (es)
NZ (1) NZ338105A (es)
PL (1) PL336037A1 (es)
PT (1) PT984774E (es)
SK (1) SK148999A3 (es)
WO (1) WO1998052547A1 (es)
ZA (1) ZA984379B (es)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391336B1 (en) * 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
DE19850445A1 (de) * 1998-11-02 2000-05-04 Falk Pharma Gmbh Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen
WO2000047644A1 (en) * 1999-02-12 2000-08-17 Universiteit Gent A biocompatible adhesive system and a bioadhesive drug delivery system with controllable release
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
DE59912559D1 (de) 1999-07-02 2005-10-20 Cognis Ip Man Gmbh Mikrokapseln - III
ATE258777T1 (de) * 1999-07-02 2004-02-15 Cognis Iberia Sl Mikrokapseln - ii
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6881420B2 (en) 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
SI1341524T1 (sl) * 2000-12-07 2012-02-29 Nycomed Gmbh Farmacevtski pripravek v obliki paste, ki obsega kislinsko labilno učinkovino
KR100413114B1 (ko) * 2001-03-30 2003-12-31 재단법인서울대학교산학협력재단 키토산으로 표면 코팅된 조직 재생용 생분해성 고분자제제 및 그 제조방법
EP1245227A1 (en) 2001-03-31 2002-10-02 Jagotec Ag A pharmaceutical tablet system that floats in the stomach for programmed release of active substance and process of producing buoyant material contained in same
US7396822B2 (en) 2001-05-24 2008-07-08 Vaxiion Therapeutics, Inc. Immunogenic minicells and methods of use
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US20040219186A1 (en) * 2001-08-16 2004-11-04 Ayres James W. Expandable gastric retention device
US20030083286A1 (en) * 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
WO2003045308A2 (en) * 2001-11-21 2003-06-05 E-Z-Em, Inc. Formulations for use in medical or diagnostic procedures
US20040071780A1 (en) * 2002-01-16 2004-04-15 Lillard James W. PACE-A microspheres for delivery of antigens
CA2517027A1 (en) 2002-02-25 2003-09-04 Vaxiion Therapeutics, Inc. Minicell compositions and methods
US20030204180A1 (en) * 2002-04-30 2003-10-30 Kimberly-Clark Worldwide, Inc. Temperature responsive delivery systems
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
WO2004021798A1 (es) * 2002-09-03 2004-03-18 Centro De Investigacion En Alimentacion Y Desarrollo A.C. Metodo de preparacion de microcapsulas de astaxantina en quitosano y producto obtenido
ES2388623T3 (es) * 2002-09-05 2012-10-17 Catherine G. Ambrose Microesferas de antibiótico para el tratamiento de infecciones y osteomielitis
US8986737B2 (en) * 2002-09-05 2015-03-24 Wm. Marsh Rice University Antibiotic microspheres for treatment and prevention of osteomyelitis and enhancement of bone regrowth
KR20050075408A (ko) * 2002-12-13 2005-07-20 시락 아게 트라마돌 및 토피라메이트를 포함하는 방출 조절형 제제
EP1587499A1 (en) * 2003-01-31 2005-10-26 Elan Pharma International Limited Nanoparticulate topiramate formulations
CN1212837C (zh) * 2003-07-02 2005-08-03 南京天泽医药科技开发有限公司 雷尼替丁微丸制剂
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US20080102114A1 (en) * 2004-04-23 2008-05-01 Panduranga Rao Koritala Microparticles and Nanoparticles for the Transmucosal Delivery of Therapeutic and Diagnostic Agents
GB0427455D0 (en) * 2004-12-15 2005-01-19 Jagotec Ag Dosage forms
US7879361B2 (en) * 2005-01-04 2011-02-01 Gp Medical, Inc. Nanoparticles for drug delivery
KR100815040B1 (ko) * 2005-01-31 2008-03-18 주식회사종근당 비스포스포네이트계 약물의 경구흡수 개선을 위한약제학적 조성물
CA2603851A1 (en) * 2005-04-11 2006-10-19 The Board Of Trustees Of The Leland Stanford Junior Unversity Multi-layer structure having a predetermined layer pattern including an agent
GB0517957D0 (en) 2005-09-03 2005-10-12 Morvus Technology Ltd Method of combating infection
US8865197B2 (en) * 2005-09-06 2014-10-21 Israel Oceanographic And Limnological Research Ltd. Food formulation for aquatic animals with integrated targeted delivery of bioactive agents
GB0526552D0 (en) 2005-12-29 2006-02-08 Morvus Technology Ltd New use
EP1993607A4 (en) * 2006-01-10 2012-03-28 Pipex Inc PHARMACEUTICAL COMPOSITIONS AND METHODS FOR OBTAINING AND MAINTAINING A TARGETABLE, STABLE COPPER RATE AND PREVENTING AND TREATING CENTRAL NERVOUS SYSTEM DISEASES RELATED TO SERIAL COPPER RATE
WO2007086078A2 (en) * 2006-01-30 2007-08-02 Panacea Biotec Ltd. Novel pharmaceutical compositions and process of preparation thereof
US8846102B2 (en) * 2006-03-30 2014-09-30 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
JP5004505B2 (ja) * 2006-05-18 2012-08-22 株式会社サンギ 口腔用組成物
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
KR20080009016A (ko) * 2006-07-21 2008-01-24 주식회사 한독약품 위 체류형 펠렛 및 이의 제조방법
GB2442202A (en) 2006-09-30 2008-04-02 Morvus Technology Ltd Vermin poison
US8895061B2 (en) * 2007-03-02 2014-11-25 Meda Pharmaceuticals Inc. Compositions comprising carisoprodol and methods of use thereof
US8178483B2 (en) * 2007-03-30 2012-05-15 Colgate-Palmolive Company Polymeric encapsulates having a quaternary ammonium salt and methods for producing the same
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
EP2205245B1 (en) 2007-10-03 2015-06-24 WisTa Laboratories Ltd. Therapeutic use of diaminophenothiazines
GB0808835D0 (en) 2008-05-15 2008-06-18 Vitra Pharmaceuticals Ltd Therapeutic compositions
ZA200903858B (en) * 2008-06-19 2013-10-30 Univ Of Witwatesrand Johannesburg Pharmaceutical dosage form
CA2729545C (en) 2008-06-25 2019-07-09 Vaxiion Therapeutics, Inc. Regulated genetic suicide mechanism compositions and methods
JP2012505203A (ja) 2008-10-08 2012-03-01 バイオプラス ライフ サイエンスズ ピーヴイティ リミテッド 持続放出性薬剤送達システム
HUE034784T2 (en) 2009-07-31 2018-02-28 Gruenenthal Gmbh Crystallization process and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
EP2544666A2 (en) 2010-03-09 2013-01-16 Council of Scientific and Industrial Research Gastroretentive, extended release composition of therapeutic agent
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
DK2675474T3 (en) 2011-02-15 2019-04-23 Vaxiion Therapeutics Llc THERAPEUTIC COMPOSITIONS AND PROCEDURES FOR TARGETED ADMINISTRATION OF BIOACTIVE MOLECULES BY BACK-TERIAL MINICLES BASED ON ANTIBODY AND FC-CONTAINING TAR-GETING MOLECULES
CA2869821C (en) 2011-06-13 2018-06-19 Rival, Societe En Commandite N,n,n-trialkylaminopolymers, methods of their preparation and uses thereof
EP2765998A1 (en) 2011-10-11 2014-08-20 Ranbaxy Laboratories Limited A gastroretentive dosage system and process of preparation thereof
EA027186B1 (ru) * 2011-12-09 2017-06-30 Юнилевер Н.В. Антимикробная композиция
EP2844301A2 (en) 2012-05-04 2015-03-11 Ineb-instituto de Engenharia Biomédica Microspheres for treating helicobacter pylori infections
SG11201500227SA (en) * 2012-08-16 2015-02-27 Univ Nanyang Tech Floating capsules encapsulating particles loaded with one or more drugs
CN113577260A (zh) 2012-10-02 2021-11-02 瓦克星治疗有限责任公司 免疫调节性小细胞及使用方法
IN2015DN04161A (es) 2012-10-16 2015-10-16 Ranbaxy Lab Ltd
KR101486132B1 (ko) * 2013-03-20 2015-01-23 씨제이헬스케어 주식회사 졸-겔 변환 특성을 갖는 고분자를 이용한 미립구의 제조방법 및 이로부터 제조된 미립구
MX2016007356A (es) 2013-12-06 2016-10-03 Advanced Bionutrition Corp Composicion para administracion oral de agentes bioactivos.
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
EP3240527B1 (en) 2014-12-31 2019-09-25 Tihminlioglu, Funda Essential oil loaded mucoadhesive nanocomposite delivery system for gastrointestinal system
WO2016115253A1 (en) 2015-01-14 2016-07-21 The Regents Of The University Ofcolordo, A Body Corporate Insulin mimotopes and methods of using the same
WO2017024059A1 (en) 2015-08-04 2017-02-09 Vaxiion Therapeutics, Llc Ionizing irradiation sterilization of bacterial minicell-based biopharmaceuticals and methods of use
CN117599029A (zh) 2016-03-17 2024-02-27 硫创治疗公司 用于控制释放半胱胺和系统治疗半胱胺敏感性病症的组合物
AU2017236977B2 (en) 2016-03-24 2022-05-26 Immunomolecular Therapeutics, Inc. Methods of treating autoimmune disease
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
CN106389386A (zh) * 2016-09-13 2017-02-15 温州生物材料与工程研究所 一种用于药物包载与缓释的生物相容性交联微纳米材料及其构建工艺
WO2018098163A1 (en) 2016-11-23 2018-05-31 Vaxiion Therapeutics, Llc Immunomodulatory & oncolytic minicells and methods of use
CA3056801A1 (en) 2017-04-28 2018-11-01 Agrospheres, Inc. Compositions and methods for the encapsulation and scalable delivery of agrochemicals
EP3684418A4 (en) 2017-09-20 2021-06-16 Thiogenesis Therapeutics, Inc. TREATMENT METHODS FOR CYSTEAMINE SENSITIVE CONDITIONS
AU2018375199B2 (en) 2017-12-01 2023-03-30 Ultragenyx Pharmaceutical Inc. Creatine prodrugs, compositions and methods of use thereof
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
EP3797818B1 (en) 2018-05-23 2023-01-18 Shanghai WD Pharmaceutical Co., Ltd Controlled-release system of active pharmaceutical ingredient and preparation method therefor
CN114191307A (zh) 2020-09-17 2022-03-18 上海汉都医药科技有限公司 一种口腔滞留装置及其制备方法
US11911513B2 (en) 2018-05-23 2024-02-27 Shanghai Wd Pharmaceutical Co., Ltd Controlled-release system of active pharmaceutical ingredient and preparation method therefor
WO2020230089A1 (en) 2019-05-14 2020-11-19 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions
CN114376087A (zh) * 2022-02-24 2022-04-22 北京九州大地生物技术集团股份有限公司 一种改善公牛繁育性能的高锌饲料添加剂及制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0163696B1 (en) 1983-11-14 1992-11-25 Columbia Laboratories, Inc. Use of a bioadhesive
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
US4895724A (en) 1985-06-07 1990-01-23 Pfizer Inc. Chitosan compositions for controlled and prolonged release of macromolecules
JPS62195323A (ja) 1986-02-24 1987-08-28 Eisai Co Ltd 胃内滞留型粒子
JPH0623202B2 (ja) 1986-07-11 1994-03-30 大日精化工業株式会社 キトサン粒体の製造方法
CA2014244A1 (en) 1989-04-13 1990-10-13 Takeda Chemical Industries, Ltd. Stabilized composition of anthracyclines
US5196409A (en) * 1989-08-20 1993-03-23 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Bisphosphonates, pharmaceutical compositions, and process for the treatment of irregularities in calcium metabolism
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
ATE141511T1 (de) 1991-04-15 1996-09-15 Applied Microbiology Inc Verwendung eines bakteriozin antibiotischen agenten zur herstellung eines arzneimittels zur behandlung von magenverstimmungen, die durch helicobacter pylori verursacht werden.
IT1250421B (it) * 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
US5198229A (en) 1991-06-05 1993-03-30 Alza Corporation Self-retaining gastrointestinal delivery device
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5571533A (en) 1992-02-07 1996-11-05 Recordati, S.A., Chemical And Pharmaceutical Company Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
JPH05339149A (ja) 1992-02-27 1993-12-21 Taisho Pharmaceut Co Ltd 徐放性懸濁製剤
US6197346B1 (en) 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
SE9201930D0 (sv) 1992-06-24 1992-06-24 Astra Ab Gastric antibacterial treatment
EP0595030A3 (en) * 1992-10-01 1995-06-07 Tanabe Seiyaku Co Composition of microspheres with several delayed release nuclei and its preparation process.
ES2068762B1 (es) * 1993-07-21 1995-12-01 Lipotec Sa Un nuevo preparado farmaceutico para mejorar la biodisponibilidad de drogas de dificil absorcion y procedimiento para su obtencion.
US5955096A (en) * 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter

Also Published As

Publication number Publication date
EP0984774A1 (en) 2000-03-15
GB2341550B (en) 2002-01-09
US6207197B1 (en) 2001-03-27
WO1998052547A1 (en) 1998-11-26
BR9809453A (pt) 2000-06-20
HUP0002935A2 (hu) 2000-12-28
GB9926405D0 (en) 2000-01-12
JP2001525848A (ja) 2001-12-11
NO995753D0 (no) 1999-11-24
PT984774E (pt) 2004-11-30
AR012854A1 (es) 2000-11-22
IL132453A0 (en) 2001-03-19
ES2226137T3 (es) 2005-03-16
DE69825049T2 (de) 2005-07-21
EP0984774B1 (en) 2004-07-14
DE69825049D1 (de) 2004-08-19
CN1257425A (zh) 2000-06-21
NZ338105A (en) 2001-04-27
AU7664298A (en) 1998-12-11
NO995753L (no) 1999-11-24
ZA984379B (en) 1999-11-22
KR20010012857A (ko) 2001-02-26
GB2341550A (en) 2000-03-22
CA2285580A1 (en) 1998-11-26
ATE270880T1 (de) 2004-07-15
AU737818B2 (en) 2001-08-30
GB9710699D0 (en) 1997-07-16
PL336037A1 (en) 2000-06-05
HUP0002935A3 (en) 2001-04-28

Similar Documents

Publication Publication Date Title
SK148999A3 (en) Gastroretentive controlled release microspheres for improved drug delivery
JP4436475B2 (ja) 固体の経口用薬剤形のための結合剤または被覆の製造に適当な水性分散液、該水性分散液の使用および再分散性粉末
US5811126A (en) Controlled release matrix for pharmaceuticals
US8709996B2 (en) Pharmaceutical treatment process using chitosan or derivative thereof
CA2169376C (en) Procedure for encapsulating nsaids
CA1317883C (en) Liquid dosage form for oral administration of a pharmaceutically active substance
JP4789806B2 (ja) パントプラゾール多粒子処方
PT642335E (pt) Preparacao de um sal de morfina de libertacao controlada
JP2000128774A (ja) 薬物を含有する球形微粒子の製法
EP2049088A2 (en) Multi-particulate formulation having tramadol in immediate and controlled release form
WO2001058424A1 (en) Floating drug delivery composition
JP4714836B2 (ja) ５―ａｓａを含有する修飾放出性経口医薬組成物および腸疾患の治療方法
CN104244927B (zh) 通过离子凝胶化生产包含双氯酚酸或其一种盐的肠溶海藻酸盐微胶囊的方法以及包含该微胶囊的多颗粒药物组合物
WO2004087111A1 (en) Oral taste masked pharmaceutical compositions
JP4357422B2 (ja) 強化味覚マスキング能および高溶出速度を有するマイクロカプセル製剤の製造方法
ES2408308T3 (es) Suspensiones analgésicas de liberación controlada
IE902829A1 (en) Microencapsulated taste-masked water-insoluble nsaid drug¹materials
ES2883352T3 (es) Forma de dosificación oral
CZ420399A3 (cs) Gastroretenční mikrosféry s regulovaným ulolňováním a zlepšenou dodávkou účinné látky
MXPA99010836A (es) Microesferas de liberacion controlada gastrorretentiva para el suministro mejorado de farmaco
Pandey et al. Evaluation of the effect of hydrophilic polymer blend to extend the release of clarithromycin from prepared microcapsules
BR102018016507A2 (pt) Composição líquida de liberação prolongada de guaifenesina
Nilkumhang Preparation and evaluation of microparticles to target drugs to different regions of the gastrointestinal tract